# EDGAR Filing Document

**Accession Number:** 0001566373
**File Stem:** 0001193125-23-062273
**Filing Date:** 2023-3
**Character Count:** 12023
**Document Hash:** 554aeb94c0b9efd279536281cddaceeb
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-062273.hdr.sgml**: 20230307

**ACCESSION NUMBER**: 0001193125-23-062273

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230307

**ITEM INFORMATION**: Other Events

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230307

**DATE AS OF CHANGE**: 20230307

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** F-star Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001566373
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 522386345
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-37718
- **FILM NUMBER:** 23711193

**BUSINESS ADDRESS:**
- **STREET 1:** 35 PARKWOOD DRIVE
- **STREET 2:** BABRAHAM RESEARCH CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB22 3AT
- **BUSINESS PHONE:** 44 1223 497400

**MAIL ADDRESS:**
- **STREET 1:** 35 PARKWOOD DRIVE
- **STREET 2:** BABRAHAM RESEARCH CAMPUS
- **CITY:** CAMBRIDGE
- **STATE:** X0
- **ZIP:** CB22 3AT

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Spring Bank Pharmaceuticals, Inc.
- **DATE OF NAME CHANGE:** 20130108

?xml version="1.0" encoding="utf-8" ? 8-K

------

### UNITED STATES

### SECURITIES AND EXCHANGE COMMISSION

#### Washington, D.C. 20549

------

### FORM 8-K

------

#### CURRENT REPORT

#### Pursuant to Section 13 or 15(d)

#### of the Securities Exchange Act of 1934

#### Date of Report (Date of earliest event reported): March 7, 2023

------

## F-STAR THERAPEUTICS, INC.

#### (Exact name of registrant as specified in its charter)

------

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-37718** | **52-2386345** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(IRS Employer**<br> **Identification No.)** |

---

#### Eddeva B920 Babraham Research Campus

#### Cambridge, United Kingdom

#### CB22 3AT

#### (Address of principal executive offices)

#### +44-1223-497400

#### Registrant's telephone number, including area code

#### Not applicable

#### (Former name or former address, if changed since last report)

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **(Title of each class)** | **(Trading<br>Symbol)** | **(Name of each exchange**<br> **on which registered)** |
| Common stock, $0.0001 par value | FSTX | The Nasdaq Stock Market<br> (Nasdaq Capital Market) |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging Growth Company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

---

| | |
|:---|:---|
| **Item 8.01** | **Other Events.**  |

---

On March 7, 2023, F-star Therapeutics, Inc. (the "Company") issued a press release announcing that the Committee on Foreign Investment in the United States has cleared the previously announced acquisition of the Company by invoX Pharma Limited ("invoX") pursuant to the Agreement and Plan of Merger, dated as of June 22, 2022, and as amended, by and among the Company, invoX, Fennec Acquisition Incorporated and Sino Biopharmaceutical Limited.

A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

#### Additional Information and Where to Find It
A tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, was filed with the SEC by invoX and Purchaser, and a Solicitation / Recommendation Statement on Schedule 14D-9 was filed with the SEC by the Company. The offer to purchase shares of Company common stock is being made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION / RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON STOCK, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER. Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the Offer, which is named in the tender offer statement. Investors may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the "Investors" section of the Company's website at www.f-star.com.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.**  |

---

(d) Exhibits.

---

| | |
|:---|:---|
| **Exhibit**<br> **No.** | **Description** |
| 99.1 | [Press Release issued March 7, 2023.](d475224dex991.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

------

#### SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **F-STAR THERAPEUTICS, INC.** | **F-STAR THERAPEUTICS, INC.** |
| Date: March 7, 2023 | /s/ Darlene Deptula-Hicks | /s/ Darlene Deptula-Hicks |
|  | Name: | Darlene Deptula-Hicks |
|  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**![LOGO](g475224dsp1.jpg)

**F-star Therapeutics Announces CFIUS Clearance for Proposed Acquisition by invoX Pharma** 

*Parties expect the merger to be completed promptly following the successful completion of the ongoing Tender Offer* 

**CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass. – March 7, 2023 (Globe Newswire) F-star Therapeutics, Inc. (NASDAQ: FSTX) ("F-star" or the "Company")**, a clinical-stage biopharmaceutical company dedicated to developing next-generation immunotherapies to transform the lives of patients with cancer, today announced that the Committee on Foreign Investment in the United States ("CFIUS") has cleared the previously announced all-cash acquisition of the Company by invoX Pharma Limited ("invoX").

The CFIUS clearance satisfies the Foreign Investment Condition of the ongoing tender offer (the "Offer"), and is the final required regulatory approval needed to complete the proposed merger. As described below, the parties expect to complete the merger promptly following the successful completion of the ongoing tender offer.

Specifically, the Offer is scheduled to expire on March 8, 2023 at 5 p.m., Eastern Time. Subject to the tendering of shares of F-star common stock representing greater than 50% of the issued and outstanding shares and the satisfaction of customary conditions, the parties expect to complete the merger promptly following this tender expiry. Previously, shares of common stock representing nearly 70% of the issued and outstanding shares had been validly tendered as of the prior expiration dates (before such dates were extended).

Stockholders who need assistance with tendering their shares of common stock of F-star, may contact the Information Agent, **Innisfree M&A Incorporated**, at the following contact information:

**Stockholders May Call Toll-Free:** 

1 (888) 750-5830 (from the U.S. or Canada)

**From outside the U.S. and Canada, please call:** 

+1 (412) 232-3651

**Banks and Brokers May Call Collect:** 

(212) 750-5833

**Email (for material requests only):** 

info@innisfreema.com

**Forward-Looking Statements** 

This press release contains forward-looking statements. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans", "will be" and similar expressions. These forward-looking statements include, without limitation, statements related to the consummation of the acquisition of the Company, the availability of mitigation measures and other statements that are not historical facts. These forward-looking statements are based on Parent's and the Company's current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the Parties' ability to complete the transaction on the proposed terms and schedule; whether sufficient stockholders of the Company tender their shares

------

in the transaction; the possibility that some of the Offer conditions will not be satisfied or waived by Parent, to the extent waiveable; and other risks related to the Company detailed from time-to-time under the caption "Risk Factors" and elsewhere in the Company's SEC filings and reports, including the Company's Annual Report on Form 10-K for the year ended December 31, 2021 and the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2022, June 30, 2022 and September 30, 2022. The Company undertakes no duty or obligation to update any forward-looking statements contained in this report as a result of new information, future events or changes in their expectations, except as required by law.

**Additional Information and Where to Find It** 

A tender offer statement on Schedule TO, including an offer to purchase, a letter of transmittal and related documents, was filed with the SEC by invoX and Purchaser, and a Solicitation / Recommendation Statement on Schedule 14D-9 was filed with the SEC by the Company. The offer to purchase shares of Company common stock is being made pursuant to the offer to purchase, the letter of transmittal and related documents filed as a part of the Schedule TO. INVESTORS AND SECURITY HOLDERS ARE URGED TO READ BOTH THE TENDER OFFER STATEMENT AND THE SOLICITATION / RECOMMENDATION STATEMENT REGARDING THE OFFER, AS THEY MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME BECAUSE THEY CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND SECURITY HOLDERS SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR COMMON STOCK, INCLUDING THE TERMS AND CONDITIONS OF THE TENDER OFFER. Investors and security holders may obtain a free copy of these statements and other documents filed with the SEC at the website maintained by the SEC at www.sec.gov or by directing such requests to the Information Agent for the Offer, which is named in the tender offer statement. Investors may also obtain, at no charge, the documents filed or furnished to the SEC by the Company under the "Investors" section of the Company's website at www.f-star.com.

**For further information, please contact:** 

**For investor inquiries:**

**John Fraunces** 

Managing Director, LifeSci Advisors, LLC

+1 917-355-2395

<u>jfraunces@lifesciadvisors.com</u>

**For media inquiries:**

**Helen Shik** 

Shik Communications LLC

+1 617-510-4373

<u>helen@shikcommunications.com</u>